# Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks

> **NCT05598814** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Vibeke Backer** · enrollment: 58 (estimated)

## Conditions studied

- Chronic Rhinosinusitis with Nasal Polyps
- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab Injection
- **PROCEDURE:** Functional Endoscopic Sinus Surgery (FESS).

## Key facts

- **NCT ID:** NCT05598814
- **Lead sponsor:** Vibeke Backer
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598814, "Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05598814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*